Latest Infectious Disease News
THURSDAY, Oct. 15, 2020 (HealthDay News) -- A new drug to treat Ebola was approved by the U.S. Food and Drug Administration on Wednesday.
Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) is a mixture of three monoclonal antibodies, and the first FDA-approved treatment for Ebola virus infection in adults and children.
The death rate after 28 days was 33.8% among the 154 patients who received Inmazeb, compared to 51% of those who received an experimental control drug.
Copyright © 2019 HealthDay. All rights reserved.